MedTech Intelligence

Prodeon Medical FDA 510(k) approved for the Urocross Expander System, a Non-Permanent Retrievable Implant for Treating Benign Prostatic Hyperplasia

The Urocross Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is ...
Business Insider

Prodeon Medical Announces Enrollment Completion for Expander-2 Pivotal Trial

SUNNYVALE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Prodeon Medical, Inc., a medical device company developing a minimally invasive treatment for lower urinary tract symptoms (LUTS) attributed to ...
Pharmabiz

Prodeon Medical’s Urocross Expander System receives US FDA 510(k) clearance for treating urinary symptoms associated with benign prostatic hyperplasia

Prodeon Medical’s Urocross Expander System receives US FDA 510(k) clearance for treating urinary symptoms associated with benign prostatic hyperplasia: Sunnyvale, California Thu ...
Business Insider

Prodeon Medical Receives FDA 510(k) Clearance for the Urocross® Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with Benign ...

SUNNYVALE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced ...
Medical Device Network on MSN

Prodeon Medical’s BPH implant gains FDA clearance

In data supporting FDA approval, 48.1% implanted with Prodeon’s Urocross saw International Prostate Symptom Score improvements.
manilatimes

Prodeon Medical Receives FDA 510(k) Clearance for the Urocross® Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with Benign ...

The Urocross® Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is intentionally retrieved, leaving no permanent foreign material behind.